0001209191-23-024386.txt : 20230414
0001209191-23-024386.hdr.sgml : 20230414
20230414191722
ACCESSION NUMBER: 0001209191-23-024386
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230412
FILED AS OF DATE: 20230414
DATE AS OF CHANGE: 20230414
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Donegan Michael C
CENTRAL INDEX KEY: 0001627810
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-00100
FILM NUMBER: 23822521
MAIL ADDRESS:
STREET 1: 6800 BROKEN SOUND PARKWAY NW
STREET 2: THIRD FLOOR
CITY: BOCA RATON
STATE: FL
ZIP: 33487-3507
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TherapeuticsMD, Inc.
CENTRAL INDEX KEY: 0000025743
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870233535
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
BUSINESS PHONE: 561-961-1900
MAIL ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
FORMER COMPANY:
FORMER CONFORMED NAME: AMHN, Inc.
DATE OF NAME CHANGE: 20090930
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF ENTERPRISES INC
DATE OF NAME CHANGE: 19970915
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF OIL CO
DATE OF NAME CHANGE: 19920703
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-12
0
0000025743
TherapeuticsMD, Inc.
TXMD
0001627810
Donegan Michael C
951 YAMATO ROAD
SUITE 220
BOCA RATON
FL
33431
0
1
0
0
Prin. Fin. and Acctg. Officer
0
Common Stock
2023-04-12
4
M
0
50000
0.00
A
61853
D
Restricted Stock Units
0.00
2023-04-12
4
M
0
50000
0.00
D
Common Stock
50000
0
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs).
Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023.
/s/ Michael C. Donegan
2023-04-14